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Healthy individuals initiate an immediate immune response to microbes by using a set of germline-encoded re-
ceptors that recognize common molecular patterns found on the surface of pathogens that are distinct from self-
antigens. This innate immune response is the ﬁrst line of defense against microorganisms in vertebrates, and
constitutes the only immune response in plants and invertebrates. The innate immune system includes cellular
components, as well as a host of soluble products (antimicrobial peptides, complement fragments, cytokines, and
chemokines). The adaptive immune response, which provides long-lasting protection, takes days to develop and
requires somatic mutations leading to the development of antigen-specific T cell receptors (cell-mediated immu-
nity) and immunoglobulins (humoral immunity). Members of the chemokine superfamily are crucially involved in
both innate and adaptive responses. We review the biological actions of the chemokine superfamily, focusing on
several functions that are relevant for both immune responses, such as cell recruitment, microbicidal activity, cell
activation, polarization of CD4þ T cells, and effects on structural cells. In particular, we will illustrate the central
role that chemokines play in host defense, best demonstrated by the tremendous number of chemokine and
chemokine receptor homologs found in microbial genomes, which deﬂect the immune response of the host.
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The superfamily of chemokines consists of more than 40
members and can be divided into four subgroups, based on
the number and spacing of the first two conserved cysteine
residues in the amino terminus: CXC (a-family), CC (b-fam-
ily), C (g-family), and CX3C (d-family) (where ‘‘X’’ is an amino
acid) (Zimmermann et al, 2003) (http://cytokine.medic.
kumamoto-u.ac.jp/). Recently, a systematic nomenclature
system for the chemokine ligands was developed (Table I)
(Zlotnik and Yoshie, 2000). Chemokines (from the contrac-
tion of the words chemotactic and cytokines) were initially
recognized for their effects on cell activation, differentiation,
and trafficking (Nickel et al, 1999). More recently, their role
has been recognized in many biological processes, such as
angiogenesis, angiostasis, hematopoiesis, organogenesis,
cell proliferation, lymphocyte polarization, apoptosis, tumor
metastasis, and host defense (Gerard and Rollins, 2001;
Murakami et al, 2004).
Functionally, chemokines can be divided into inducible or
‘‘inflammatory’’ chemokines and constitutively expressed or
‘‘homeostatic’’ chemokines (Table I) (Lukacs, 2001). Inflam-
matory chemokines are critical for attracting a diverse set of
effector leukocytes to inflammatory sites and as such they
are thought to play a key role in the innate immune response
by recruiting neutrophils, monocytes/macrophages, dendri-
tic cells (DC), and natural killer (NK) cells. Inflammatory
chemokines typically bind to more than one chemokine
receptor, which suggests that there is considerable
redundancy in the inflammatory chemokine network. For
example, numerous CC chemokines such as CC-chemo-
kine ligand (CCL)5, CCL7, CCL11, CCL13, CCL24, CCL26,
and CCL28 bind to CC-chemokine receptor (CCR)3. These
molecules are, however, thought to be non-redundant, as
they differ in stimuli that induce their release, cells that
produce them, their binding affinities as well as biological
potencies and efficacies (Zimmermann et al, 2003). Further-
more, these secreted chemokines may be modified within
their local tissue environment by enzymes such as dipep-
tidyl peptidase IV (CD26), which cleaves amino-terminal
amino acids, resulting in changes in their biological potency
or even in the development of a functional antagonist. For
example, the truncated version of eotaxin can no longer
induce a CCR3 signal and in fact desensitizes the CCR3
receptor (Struyf et al, 1999). Many other enzymes frequently
found at sites of inflammation or infection, such as neutro-
phil elastase, cathepsins, chymotrypsin, and matrix metal-
loproteinases can also modify chemokines at the amino
Abbreviations: APC, antigen-presenting cell; CCL, CC-chemokine
ligand; CCR, CC-chemokine receptor; CpG-DNA, unmethylated
poly-cytosine or -guanosine dinucleotides; CX3CR, CX3C chemo-
kine receptor; CXCL, CXC chemokine ligand; CXCR, CXC chemo-
kine receptor; DARC, Duffy antigen receptor for chemokines; DC,
dendritic cell; ELR, N-terminal ELR (Glu–Leu–Arg) amino acid motif
(in CXC chemokines); GPCR, G-protein-coupled seven-transmem-
brane receptor; LC, Langerhans cell; LPS, lipopolysacharide;
MCAF, monocyte chemotactic and activating factor; MIP, ma-
crophage inflammatory protein; MYD88, myeloid differentiation
factor 88; NK, natural killer; NOD, nucleotide-binding oligomerizat-
ion domain; PAMP, pathogen-associated molecular pattern; PGN,
peptidoglycan; PRR, pattern-recognition receptor; RBC, red blood
cell; TLR, toll-like receptor; vCk, viral homolog of chemokines;
vCkBP, virally produced chemokine-binding protein; vCkR, viral
homolog of chemokine receptors
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terminus, altering their receptor–ligand interaction and
therefore their function (Rot and von Andrian, 2004). This
post-translational modification has been utilized by the
helminthic parasite, Necator americanus, which releases an
enzyme that inactivates eotaxin thereby preventing the re-
cruitment and activation of eosinophils, providing a survival
advantage to the parasite (Culley et al, 2000).
Homeostatic chemokine receptor/ligand pairs (CXC
chemokine receptor (CXCR)4–CXC chemokine ligand
(CXCL)12, CXCR5–CXCL13, CCR6–CCL20, CCR7–CCL19,
CCR7–CCL21) are important for migration of antigen-pre-
senting cells (APC) and lymphocytes into the lymph node,
where antigen education and immune surveillance occur,
whereas other homeostatic chemokine receptor/ligand
pairs (CCR4–CCL17, CCR4–CCL22, CCR8–CCL1, CCR9–
CCL25, CCR10–CCL27, CCR10–CCL28) are important for
effector T cells to reach tissues that contain their cognate
antigen (reviewed in Rot and von Andrian, 2004). Both ac-
tions are critically important for an effective adaptive im-
mune response. Not surprisingly, in studies where several of
these chemokine receptors were knocked out, the devel-
opment of normal lymphoid architecture was affected,
Table I. Chemokine ligands and receptors
Name Human ligand
Receptor agonist
or [antagonist]
CXC family
CXCL1 GROa/MGSA-a CXCR2
CXCL2 GROb/MGSA-b CXCR2
CXCL3 GROg/MGSA-g CXCR2
CXCL4 PF4
CXCL5 ENA-78 CXCR2
CXCL6 GCP-2 CXCR1, CXCR2
CXCL7 NAP-2 CXCR2
CXCL8 IL-8 CXCR1, CXCR2
CXCL9 MIG CXCR3 [CCR3]
CXCL10 IP-10 CXCR3 [CCR3]
CXCL11 I-TAC CXCR3 [CCR3]
CXCL12 SDF-1a/b CXCR4
CXCL13 BLC/BCA-1 CXCR5
CXCL14 BRAK/bolekine
CXCL15 —
CXCL16 SR-PSOX CXCR6
CC family
CCL1 I-309 CCR8
CCL2 MCP-1/MCAF CCR2
CCL3 MIP-1a/LD78a CCR1/CCR5
CCL4 MIP-1b CCR5
CCL5 RANTES CCR1, CCR3, CCR5
CCL6 —
CCL7 MCP-3 CCR1, CCR2, CCR3
[CCR5]
CCL8 MCP-2 CCR3
CCL9/10 —
CCL11 Eotaxin CCR3, CCR5 [CCR2]
CCL12 — CCR2
CCL13 MCP-4 CCR2, CCR3
CCL14 HCC-1 CCR1
CCL15 HCC-2/Lkn-1/
MIP1d
CCR1, CCR3
CCL16 HCC-4/LEC CCR1
CCL17 TARC CCR4
CCL18 DC-CK1/PARC/
AMAC-1
[CCR3]
CCL19 MIP-3b/ELC/
exodus-3
CCR7
CCL20 MIP-3a/LARC/
exodus-1
CCR6
CCL21 6Ckine/SLC/
exodus-2
CCR7
CCL22 MDC/STCP-1 CCR4
Table I. Continued
Name Human ligand
Receptor agonist
or [antagonist]
CCL23 MPIF-1 CCR1
CCL24 MPIF-2/Eotaxin-2 CCR3
CCL25 TECK CCR9
CCL26 Eotaxin-3 CCR3 [CCR1, CCR2,
CCR5]
CCL27 CTACK/ILC CCR10
CCL28 MEC CCR3, CCR10
C family
XCL1 Lymphotactin/
SCM-1a/ATAC
XCR1
XCL2 SCM-1b XCR1
CX3C family
CX3CL1 Fractalkine CX3CR1
New nomenclature as proposed by Zlotnik and Yoshi (2000) is shown,
with older nomenclature indicated in the second column. A dash indi-
cates that the homolog has not been identified. Bolded chemokines/
receptors are homeostatic or constitutive chemokines.
CXCL, CXC chemokine ligand; GRO, Growth-regulated oncogene;
MGSA, melanoma growth stimulatory activity; PF, platelet factor; ENA-78,
epithelial neutrophil activating peptide 78; GCP, granulocyte chemotactic
protein; NAP, neutrophil-activating peptide; MIG, monokine-induced by
IFNg; IP, IFNg-inducible protein; I-TAC, IFN-inducible T-cell chemoat-
tractant; SDF-1, stromal cell-derived factor 1; BCA, B-cell attracting
chemokine; BRAK, breast- and kidney-expressed chemokine; MCP,
monocyte chemoattractant protein; MCAF, monocyte chemotactic and
activating factor; MIP, macrophage inflammatory protein; HCC, human
CC chemokine; Lkn, leukotactin; LEC, liver-expressed chemokine; TARC,
thymus- and activation-regulated chemokine; DC-CK1, dendritic cell-de-
rived CC chemokine, PARC, pulmonary- and activation-regulated chemo-
kine; AMAC, alternative macrophage activation-associated CC
chemokine; ELC, EBL-1 ligand chemokine; LARC, liver- and activation-
regulated chemokine; SLC, secondary lymphoid tissue chemokine; MDC,
monocyte-derived chemokine; STCP, stimulated T cell chemoattractant
protein; MPIF, myeloid progenitor inhibitory factor; TECK, thymus-ex-
pressed chemokine; CTACK, cutaneous T cell-activating chemokine; ILC,
IL-11 recepter a-locus chemokine; MEC, mucosae-associated epithelial
chemokine; SCM, Single C motif; ATAC, activation-induced, chemokine-
related molecule (modified from Zimmermann et al, 2003).
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resulting in altered B cell migration (CXCR5 KO), immature
DC migration (CCR6 KO), lymphocyte, and activated DC
migration (CCR7 KO) (Muller et al, 2002). In contrast to in-
flammatory chemokines, homeostatic chemokines display a
more monogamous receptor usage. It is important to rec-
ognize, however, that some chemokines clearly do not fit
either paradigm. For example, CCL22 is not only expressed
in secondary lymphoid tissue but also in inflamed lungs
(Godiska et al, 1997). Similarly, CCL21 is constitutively ex-
pressed on the luminal side of high endothelial venules and
as such is important in the homeostatic movement of naı¨ve
T and B cells to lymphoid organs. But CCL21 can also be
induced on afferent lymphatics by inflammatory stimuli,
thereby boosting the numbers of DC that reach the draining
lymph node (see Leukocyte recruitment) (MartIn-Fontecha
et al, 2003).
Chemokines mediate their biological effects by binding
to G-protein-coupled seven-transmembrane receptors
(GPCR) that can activate an array of signaling pathways.
Ten CC (CCR1-10), seven CXC (CXCR1-6 and CXCR3B),
one CX3C (CX3C chemokine receptor (CX3CR)1), and one C
(XCR1) receptors have been identified (Table I), in addition
to two decoy (non-signaling) chemokine receptors: Duffy an-
tigen receptor for chemokines (DARC) previously known as
the erythrocyte antigen Duffy, and D6. Both of these decoy
receptors bind primarily inflammatory chemokines of the
CXC and CC subfamilies, respectively (Gardner et al, 2004).
Recent studies have demonstrated that these decoy re-
ceptors have several functions, including internalization
and/or degradation of inflammatory, but not homeostatic,
chemokines (the so-called ‘‘sink’’ hypothesis) (Nickel et al,
1999). Other than DARC expression on red blood cells
(RBC), the expression of these decoy receptors is largely
limited to endothelial cells, such as post-capillary venules
for DARC and lymphatics for D6. Endothelial-expressed
DARC has been shown to transport chemokines from the
abluminal to the luminal surface for presentation of the
chemokine to circulating leukocytes (Lee et al, 2003). This
function would suggest that DARC may also have a pro-
inflammatory function. D6, expressed on lymphatic end-
othelial cells, does not mediate such chemokine transcy-
tosis and is thought to function as a clearance mechanism
for inflammatory chemokines to prevent their diffusion to
draining lymph nodes via afferent lymphatics (Fra et al,
2003). The D6-deficient mouse was recently shown to have
an enhanced inflammatory response to phorbol esters that
was characterized by a notable T cell and mast cell infiltrate
and a psoriasiform change to the epithelium (Jamieson et al,
2005).
DARC was first recognized as the receptor utilized by
Plasmodium vivax to infect erythrocytes (Miller, 1975). The
majority of Africans and about 70% of African Americans do
not express DARC on their RBC. This confers an evolution-
ary advantage, as DARC-negative erythrocytes are resistant
to Malaria, which is endemic in most of the African conti-
nent. There is evidence that the lack of DARC on RBC leads
to a greater susceptibility to tumors (such as prostate can-
cer) and inflammatory diseases (such as graft rejection and
asthma) due to the reduced ‘‘sink’’ of angiogenic and in-
flammatory chemokines (Lentsch, 2002; Akalin and Neylan,
2003). This anti-inflammatory effect has been shown more
directly in an eosinophil shape change assay, which is a
surrogate for chemotaxis. In this assay, the magnitude of
the shape change observed in response to whole-blood
stimulation with the CCR3 ligand, CCL11, was diminished in
subjects who were DARC positive (Bryan et al, 2002).
Although the expression of DARC on RBC is genetically
determined, endothelial DARC mRNA and protein can be
upregulated in response to inflammatory or infectious stim-
uli, suggesting that the chemokine-binding properties of
Duffy antigen may be biologically relevant during lip-
opolysacharide (LPS)-induced inflammation (Dawson et al,
2000). Similarly, DARC-null mice, lacking the Duffy antigen
on RBC and endothelial cells, develop significantly greater
inflammation in the lungs and liver following challenge with
lipopolysaccharide (Table II) (Dawson et al, 2000). The hy-
pothesis that has therefore emerged is that DARC partic-
ipates in regulating effective chemokine concentrations in
tissue but whether the net effect is anti- or pro-inflammatory
may depend on the stimulus, the organ, and the relative
effects of DARC-expressing RBC versus endothelial cells.
Less is known about the role of the D6 decoy receptor in
health and diseased states.
With regard to chemokine receptor interactions, CC
receptors bind mainly CC chemokines, and CXC receptors
bind preferentially CXC chemokines. There are several
known exceptions, such as the CXC ligands CXCL9,
CXCL10, and CXCL11, which bind CCR3 and are function-
al antagonists (Fulkerson et al, 2004). Even within a chemo-
kine subfamily (and its receptors), chemokines can have
agonistic actions on one receptor and antagonistic actions
on another. An example would be CCL11, which can signal
through CCR3 and CCR5, but acts as an antagonist when
binding to CCR2 (Ogilvie et al, 2001).
In summary, chemokines are important, multifunctional
mediators of inflammation and immunity. The complexity of
their biological role is suggested by many of their features,
from the large number of members in the superfamily, to
their complex ligand–receptor interactions, the multiple
conformations of the receptor (homo- and hetero-dime-
rization), as well as naturally-occurring splice variants, po-
lymorphisms, and post-translational modifications (obser-
ved with locally released proteases); which all play a role in
finely tuning their local biological actions (Mellado et al,
2001; Comerford and Nibbs, 2005).
Chemokine Functions
Leukocyte recruitment The mechanisms responsible for
selective recruitment of leukocytes into tissues (under
homeostatic or inflammatory conditions) are thought to in-
volve cytokines that activate the expression of the endo-
thelial adhesion molecules E- and P-selectin, ICAM-1 and
VCAM-1, as well as leukocyte-specific chemoattractants
such as chemokines (Bochner, 2000). The earliest step in
leukocyte recruitment involves the rolling of leukocytes on
the endothelial surface. This process is primarily mediated
by the selectin family with the exception of the T cell, which
like the eosinophil, may also use VLA-4/VCAM-1 for rolling
(Sriramarao et al, 1994; Alon et al, 1995). Rolling is followed
by firm adhesion, which is mediated by leukocyte b1 and b2
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Table II. Mouse models demonstrate that the chemokine family is important in host defense
Knockout
Clinical and immunological consequence
MicrobeReferencea
Receptors
CCR1
Reduced inflammation, increased mortality Paramyxovirus
Domachowske, J Immunol, 2000
Increased susceptibility to infection Toxoplasma gondii
Khan, J Immunol, 2001
Increased susceptibility to infection Aspergillus fumigatus
Gao, J Exp Med, 1997
Smaller lesions containing fewer parasites Leishmania major
Rodriguez-Sosa, Immunol Cell Biol, 2003
No effect on corneal PMN or opacities Onchocerciasis
Hall, J Immunol, 2001
CCR2
Defective macrophage recruitment and host defense Listeria monocytogenes
Kurihara, J Exp Med, 1997
Decreased macrophage and CD8þ T cell recruitment Cryptococcus neoformans
Huffnagle, Immunopharmacology, 2000
Prolonged pulmonary infection C. neoformans
Up to 800-fold greater dissemination to spleen and brain
Reduced macrophage recruitment
Traynor, J Immunol, 2000
Failure to control infection Leishmania major
Block in infection-induced relocalization of splenic DC
Sato, J Exp Med, 2000
Significantly decreased survival Mycobacterium tuberculosis
Macrophages exhibit recruitment defects to lungs
100-fold higher bacterial load in lungs
Peters, PNAS, 2001
CCR4
Decreased mortality in endotoxic shock LPS
Chvatchko, J Exp Med, 2000
CCR5
Impaired macrophage function ANCE Listeria monocytogenes
Reduced efficiency in bacterial clear
Zhou, J Immunol, 1998
No protection against infection or death Yersinia
Elvin Nature, 2004
Decreased survival C. neoformans
Defect in leukocyte migration to brain
Huffnagle, J Immunol, 1999
Lower parasite burden in liver Leishmania donovani
Sato, J Immunol, 1999
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Table II. Continued
Knockout
Clinical and immunological consequence
MicrobeReferencea
Reduced macrophage infiltration Mouse hepatitis virus
Glass, Virology, 2001
Antiviral T-cell response appears to be augmented Lymphocytic
choriomeningitis virus
Nansen, Immunobiology, 2002
Decreased susceptibility to Cryptosporidiosis Cryptosporidium parvum
Campbell, J Parasitol, 2002
Decreased susceptibility to cerebral malaria Plasmodium berghei
Belnoue, Blood, 2003
IL8Rh/CXCR2
Dysfunctional neutrophil migration Escherichia coli
Godaly, J Immunol, 2000
Subepithelial neutrophil entrapment and renal scarring E. coli
Hang, J Infect Dis, 2000
Enhanced susceptibility to pyelonephritis E. coli
Frendeus, J Exp Med, 2000
Frendeus, J Infect Dis, 2001
Impaired neutrophil recruitment Toxoplasma gondii
Del Rio, J Immunol, 2001
Impaired neutrophil extravasation S. aureus
Increased bacterial burden
Kielian, J Immunol, 2001
Reduction in neutrophil recruitment Mycobacterium avium
Goncalves, Scand J Immunol, 2002
Enhanced susceptibility to herpetic stromal keratitis HSV-1
Banerjee, J Immunol, 2004
Decrease in Lyme arthritis severity B. burgdorferi
Brown, J Immunol, 2003
Decreased mucus production and airway hyperreactivity Respiratory syncytial virus
Miller, J Immunol, 2003
CXCR5
Accelerated transfer of intraperitoneally administered prions into the spinal cord Prions
Prinz, Nature, 2003
DARC
Increased inflammatory infiltrates in lung and liver LPS
Dawson TC, Blood, 2000
Ligands
CCL2
Reduced NKT cell recruitment Cryptococcus neoformans
Kawakami, J Immunol, 2001
Enhanced susceptibility to gingivitis Streptococcus mutans,
Streptococcus intermedius,
Peptostreptococcus micros,
Porphyromonas gingivalis,
Prevotella intermedius,
Fusobacterium nucleatum
Chae, Infect Immun, 2002
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integrins binding to endothelial adhesion molecules (ICAM-
1 and VCAM-1) (Bochner, 2000).
Chemokines exert their effect at two points in the extra-
vasation process. First, they transiently activate integrins on
the leukocyte surface, which results in enhanced avidity of
the cell for the endothelial adhesion molecules (ICAM-1 and/
or VCAM-1) (Constantin et al, 2000). In so doing, they facil-
itate the transition of leukocytes from fast to slow rolling and
ultimately, to firm adhesion. Chemokines are presented to
the rolling leukocyte bound to glycosaminoglycans present
on the apical surface of endothelial cells. Second after
transendothelial migration, the chemokine gradients found
within the tissues determine where the leukocytes will local-
ize, in conjunction with integrin-based adhesion signals that
the leukocytes experience to extracellular matrix proteins.
Interestingly, it has recently been appreciated that sev-
eral chemokines (CXCL12 and CCL26) mediate chemore-
pulsion through CXCR4 and CCR2, respectively (Poznansky
et al, 2002; Ogilvie et al, 2003). This is thought to be relevant
for leukocyte departure from tissue compartments such as
the bone marrow and thymus.
The chemotactic actions of chemokines are thought to
be critical for the recruitment and activation of leukocytes
important in the innate immune response such as neu-
trophils, monocytes, DC, and NK cells as well as those in-
volved in the adaptive immune response (naı¨ve and memory
CD4 and CD8 cells, and immature DC).
Innate immunity A key element in the initiation of the innate
immune response is the detection of components com-
Table II. Continued
Knockout
Clinical and immunological consequence
MicrobeReferencea
Failure to expel infection Trichuris muris
deSchoolmester, J Immunol, 2003
CCL3
Reduced antiviral host defense Pneumonia virus
Domachowske, J Immunol, 2000
Inhibited inflammatory and protective liver responses Murine cytomegalovirus
Salazar-Mather, J Exp Med, 1998
Decreased resistance to infection Murine cytomegalovirus
Reduced NK cell accumulation
Salazar-Mather, J Clin Invest, 2000
Impaired survival
Lindell, Infect Immun, 2001
Klebsiella pneumonia
Decreased survival C. neoformans
Olszewskin, J Immunol, 2000
Impaired prevention of eosinophilic pneumonia C. neoformans
Olszewski, Infect Immun, 2001
Reduced protective innate immunity against sepsis C. neoformans
Cecal ligation and puncture
Takahashi, J Leuk Biol, 2002
Delayed viral clearance Mouse hepatitis virus
Trifilo, J Virol, 2003
Lower parasite burden in liver Leishmani donovani
Sato, J Immunol, 1999
CCL11
Suppressed endotoxemia-associated peritoneal neutrophils LPS
Cheng, Exp Mol Pathol, 2002
CXCL15
Impaired pulmonary host defense Klebsiella pneumonia
Chen, J Immunol, 2001
Knockout mice (in bold) experienced improved survival advantage compared with wild-type mice.
aAll references in this table can be found in the supplemental material available online for this article.
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monly found on the invading pathogen that are not normally
found on host cells. These components are constitutive and
conserved products of microbial metabolism and include
among others, LPS, lipoproteins, peptidoglycan (PGN), and
unmethylated DNA containing a CpG motif (CpG-DNA).
These pathogen-associated molecular patterns (or PAMP)
are recognized by receptors of the innate immune system,
which are referred to as pattern-recognition receptors
(PRR), such as nucleotide-binding site leucine-rich repeat
proteins (NOD1 and NOD2) and Toll-like receptors (TLR)
(see accompanying Modlin review). The major inflammatory
cytokines released by epithelial cells or DCs as a direct
consequence of PRR signaling include IL-1, TNFa, Interfer-
ons, IL-4, IL-5, IL-6, IL-13, IL-17, and chemokines (Kopp
and Medzhitov, 2003). Many of these molecules can have
autocrine and paracrine effects, amplifying chemokine re-
lease by adjacent cells. When the innate response results in
the production of a polarized (Th1 vs Th2) cytokine profile, a
unique profile of chemokines is released and referred to as
Th1 chemokines or Th2 chemokines (see below). Interest-
ingly, the most potent stimuli for chemokine production by
structural cells or APC are those that signal through myeloid
differentiation factor 88 (MyD88) signaling (such as TLR, IL-
1, and TNFa) (Kopp and Medzhitov, 2003), although even
antimicrobial peptides, like the a defensins (human neutro-
phil peptide 1–3) have been shown to augment the expres-
sion and/or production of the neutrophil chemoattractants,
CXCL8 and CXCL5, from bronchial epithelial cells (Yang
et al, 2004).
The innate response is best characterized by the
recruitment of leukocytes such as phagocytic granulocytes,
monocyte/macrophages that are capable of engulfing or
combating the pathogen with a variety of humoral media-
tors such as antimicrobial substances, activated compo-
nents of the complement cascade, and cytokines. In gen-
eral, neutrophils expressing CXCR1 and CXCR2 arrive early
in response to specific CXC ligands containing the Glu–
Leu–Arg amino acid motif in their NH2 terminus, also called
ELRþpos CXC chemokines, such as CXCL8, CXCL5, and
CXCL1 (Rot and von Andrian, 2004) (Figure 1). Mice lacking
CXCR2 have a defect in neutrophil-mediated killing and are
highly susceptible to infection with Staphylococcus aureus,
Mycobacterium avium, and Toxoplasma gondii (Table II) (Del
Rio et al, 2001; Kielian et al, 2001; Goncalves and Appel-
berg, 2002). The CC chemokines, CCL3 and CCL4, are
not chemotactic for neutrophils in vitro, but promote local
influx of neutrophils in vivo, which is CCR1 mediated (Lee
et al, 2000). CCR1 appears to be involved in neutrophil-me-
diated host defense, as the CCR1 knockout mouse is more
susceptible to infection with Aspergillus fumigatus, a ubiqui-
tous fungus that causes invasive and highly lethal infections
in humans and mice mainly when neutrophil number or func-
tion are impaired (Table II) (Gao et al, 1997). In contrast,
CCR1 was not responsible for the neutrophil recruitment
observed in the cornea in the helminth-mediated keratitis
called Onchocerciasis or river blindness (Hall et al, 2001).
Collectively, these findings suggest that the role CCR1 plays
in neutrophil recruitment and function is organ specific. Mon-
ocytes and other mononuclear cells expressing CCR1,
CCR2, and CCR5 arrive later primarily in response to
CCL2, CCL3, and CCL5 (Rot and von Andrian, 2004).
NK cells are involved in the early protection against viral
infection. These cells do not undergo genetic recombination
events to increase their affinity for particular ligands, and
are thus considered part of the innate immune system. NK
cells are found predominantly in peripheral blood and
spleen. Resting CD56dim NK cells do not express the
chemokine receptor CCR7, which is important for cell hom-
ing to secondary lymphoid organs (Maghazachi, 2003).
Consequently, NK cells are thought to migrate to peripheral
non-lymphoid tissues. The expression of chemokine recep-
tors by human NK cells is a subject of controversy. Camp-
bell et al (2001) found high-level expression of CXCR1,
CXCR4 and CX3CR1 and low-level expression of CXCR2
and CXCR3). In contrast, Inngjerdingen et al (2001), report-
ed that purified, resting human NK cells expressed CXCR4
but not CXCR1, CXCR2, CXCR3, or CX3CR1. Functional
studies have demonstrated that resting human NK cells
migrate in response to ligands for CXCR3 (CXCL9-11),
CXCR4 (CXCL12), XCR1 (XCL1), and CX3CR1 (CX3CL1),
strongly suggesting that these receptors are in fact ex-
pressed (Inngjerdingen et al, 2001). Following in vitro acti-
vation, human NK cells upregulate CCR2, CCR4, CCR7,
and CCR8 and exhibit increased chemotactic responses to
known ligands for these receptors (Inngjerdingen et al,
2001). Macrophage-inducible protein (CCL3)-1a recruits NK
cells toward the liver of cytomegalovirus-infected mice, re-
sulting in increased inflammation and decreased suscepti-
bility to infection with this virus (Salazar-Mather et al, 1998).
In summary, chemokines not only recruit NK cells to in-
flammatory sites in vivo, but they potentiate NK cell-medi-
ated killing (Taub et al, 1995).
Adaptive immunity The orchestration of the adaptive im-
mune response is mediated by both homeostatic and in-
flammatory chemokines (Figure 1). The binding of the
homeostatic chemokines CCL19 and CCL21 to CCR7 on
naı¨ve T cells, B cells, mature DC/LC (Langerhans cells) and
CD56bright NK cells induce their migration to the T cell zone
of secondary lymphoid organs (Ono et al, 2002). The B cells
ultimately localize to the follicles of the lymph node in re-
sponse to the homeostatic CXCR5 ligand, CXCL13. There-
fore, the homeostatic chemokines are important for the
development and maintenance of lymph node architecture
(Muller et al, 2002). Inflammatory chemokines, on the other
hand, are responsible for the recruitment of immature DC to
sites of inflammation, and include ligands for CXCR1,
CCR1, CCR2, CCR5, and CCR6 (Caux et al, 2000).
We recently demonstrated that epithelial cells express
mRNA for all TLR, and that several known TLR ligands
activate epithelial cells to express chemokines, cytokines,
and host defense molecules, including acute-phase pro-
teins and complement proteins (Sha et al, 2004). Among
the induced genes were CCL20 (the CCR6 ligand) and
GM-CSF, which would be expected to recruit and acti-
vate immature DC and LC that are important initiators
of an adaptive immune response. It is interesting to
note that keratinocyte expression of CCL20 is induced by
IL-1 and TNFa and not surprisingly, CCL20 has been
detected in the epidermis of skin biopsies from subjects
with psoriasis, contact dermatitis, and mycosis fungoides,
suggesting that these diseases develop in response to mi-
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crobial invasion or injury (Dieu-Nosjean et al, 2000; Schmuth
et al, 2002).
In addition to its effects on immature DC, CCL20 has also
been shown to induce the selective migration of bone mar-
row-derived LC precursors and freshly isolated LC as well
as memory T cells to sites of inflammation. (Dieu-Nosjean
et al, 2000; Homey et al, 2000). Interestingly, the CCR6-
deficient mouse had reduced CD4þ cell recruitment in a
contact hypersensitivity and DTH model but had no effect
on epidermal or dermal LC numbers, suggesting that there
may be other pathways to recruit LC to the skin under
physiological conditions (Varona et al, 2001). Chemokine
Figure 1
The Role of Chemokines in the Innate and Adaptive Immune Responses in the Skin. Chemokines orchestrate effects that impact both innate
and adaptive immune responses. Microbial invasion or injury (upper left) initiates innate immune pathways at least in part through TLR signaling. This
results in the release of inflammatory cytokines and chemokines from both structural cells (epithelial and fibroblasts) and APC. These mediators are
responsible for the activation of the endothelium (e.g., upregulation of adhesion molecules) and the recruitment and activation of leukocytes critical
for innate immune responses (neutrophils, eosinophils, basophils, NK cells, monocytes, and immature DC/LC precursors). Several chemokines
produced by keratinocytes are also thought to act as antimicrobial peptides (CCL20, CXCL9-11), directly killing microbes. Keratinocytes express
several chemokine receptors (CCR3, CXCR1, and CXCR2) which likely play a role in the wound repair response (epithelial proliferation, and
chemotaxis) and release chemokines important for angiogenesis following an innate insult. When resident, immature LC/DC are exposed to a
danger signal (e.g., pathogen or injury) they mature resulting in a reduction in CCR6 and enhanced CCR7 expression. This releases the LC/DC from
effects of the keratinocyte-derived CCR6 ligand (CCL20), and enables them to respond to the CCR7 ligand (CCL21), released by lymphatic vessels
and promotes their migration to the draining LN. Maintenance of the normal LN architecture under homeostatic or inflammatory conditions is largely
due to the directional effects of chemokines released by stromal cells of the lymph node. The CCR7 ligands (CCL19, CCL21) are responsible for the
recruitment of naı¨ve T cells to the T-zone and the CXCR5 ligand (CXCL13) is responsible for recruitment of B cells and T helper cells to the B cell
follicle. The polarization of T helper cells into Th1 versus Th2 cells may be in part determined by the relative effects of CCR5 or CCR2 ligands,
respectively. The trafficking of these memory cells back to the tissue sites is also under chemokine control with Th1 cells responding to CXCR3
ligands (CCL9-11) and CCR5 ligands (CCL3-5) and Th2 cells responding primarily to the CCR4 and CCR8 ligands (CCL1, CCL17 and CCL22). The
specific recruitment of skin homing memory Tcells, identified by the surface marker, CLA is under the influence of the CCR10 ligand (CCL27) in both
Th1- and Th2-mediated skin diseases. In the case of atopic dermatitis (Th2 polarized), CCR4 ligands (CCL17 and CCL22) seem to be critical and in
the case of psoriasis (Th1 polarized), the CCR6 ligand (CCL20) seems to be pivotal. There are several known mechanisms responsible for containing
the inflammatory response initiated by inducible chemokines and include among other things; decoy receptors (DARC on RBC and endothelial cells,
D6 on lymphatic endothelium) and tissue enzymes which can cleave and in some cases inactivate chemokines.
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ligands and receptors are also critical for the trafficking of
epidermal LC to regional lymph nodes after a ‘‘danger sig-
nal’’ or inflammatory stimuli. After such a signal, LC undergo
a maturation process that leads to enhanced CCR7 and the
loss of CCR6 expression (Jakob et al, 2001). The loss of
CCR6 is thought to release LC from the local CCL20-rich
environment, and enables them to respond to CCR7 ligands
such as CCL19 and CCL21, both of which are constitutively
expressed in T cell areas of regional lymph nodes (Jakob
et al, 2001). Studies in CCR7-deficient mice have clearly
demonstrated that this receptor is indispensable for activa-
tion-induced but is also important for steady-state migration
of LC into afferent lymphatics (Ohl et al, 2004). Migration
under steady-state conditions is thought to be important in
the maintenance of peripheral tolerance. CCL21 is also
constitutively expressed on lymphatic vessels and blocking
antibody studies confirmed the involvement of CCL21 in the
entry of activated LC into lymphatic vessels (Saeki et al,
1999). In plt/plt mice, which carry a spontaneous mutation
that abolishes CCL19 expression and restricts CCL21 ex-
pression to the lymphatic endothelium, LC and also naı¨ve T
cells fail to enter the T cell zone of secondary lymphoid or-
gans (Gunn et al, 1999). Thus, migration of mature DC and
LC may be regulated at the level of entry into into lymphatic
vessels via upregulation of CCR7 and CCL19/CCL21. In
summary, a switch in chemokine receptor expression pro-
motes LC trafficking from sites of epidermal antigen uptake
to lymphoid organs. The restricted set of chemokine recep-
tors expressed by trafficking LC stands in striking contrast
to the broader chemokine receptor panel of DC that appears
under inflammatory conditions.
Several studies have demonstrated that human Th1 and
Th2 cells differentially express chemokine receptors. The
C-C chemokines, CCL1, CCL11, CCL17, and CCL22, se-
lectively recruit Th2 lymphocytes. This chemotaxis is me-
diated primarily by expression of CCR4 and CCR8 on Th2
cells with a potential role for CCR3 in highly polarized cells
(Ono et al, 2003). CCR5 and CXCR3 are preferentially
expressed on Th1 cells producing IFN-g, and as a conse-
quence, they migrate in response to CCL3, CCL4, and
CCL5 or the ELRneg CXC chemokines, respectively (Luther
and Cyster 2001). Interestingly, memory T cells that home
preferentially to the skin also express CCR4, regardless of
their polarized phenotype (Th1 or Th2) (Andrew et al, 2001).
These skin-homing cells express a unique receptor
called cutaneous lymphocyte-associated antigen (CLA)
(Beck and Leung, 2000). This notion emerged from
immunohistochemical evidence showing that the majority
of the T lymphocytes infiltrating the skin in a wide variety of
inflammatory and neoplastic conditions expressed CLA,
whereas very few CLAþ Tcells are found at extracutaneous
inflammatory sites (Beck and Leung, 2000). High expression
of CCR4 has been found on skin-homing lymphocytes, and
high levels of its ligands (CCL17 and CCL22) have been
detected in the skin of a mouse model of atopic dermatitis
(AD) (NC/Nga) and in skin biopsies and serum of AD sub-
jects (Vestergaard et al, 1999; Galli et al, 2000; Kakinuma
et al, 2001; Fujisawa et al, 2002). Interestingly, serum CCL17
levels are much higher in subjects with AD compared
with psoriasis or healthy controls, suggesting that another
chemokine receptor besides CCR4 may be utilized for
memory T cell recruitment in a Th1-polarized disease (Kaki-
numa et al, 2001; Vestergaard et al, 2003). Both CCL20/
CCR6 and CCL27/CCR10 have also been implicated in the
skin homing of memory T lymphocytes (Morales et al, 1999;
Homey et al, 2000). The marked upregulation of CCL20 and
its receptor, CCR6, in psoriasis and the enhanced chemo-
tactic response of psoriatic lymphocytes compared with
normal controls to CCL20 suggest that CCL20/CCR6 may
be more relevant for the Th1 lymphocyte recruitment
observed in this disease (Homey et al, 2000). The C-C
chemokine, CCL27, constitutively expressed by human
keratinocytes, selectively induces the migration of CLAþ T
cells in vitro by binding to CCR10, and has been postulated
to be involved in basal memory T cell trafficking to the skin
(Morales et al, 1999). CCL27, however, can be upregulated
by inflammatory signals (IL-1 and TNF-a) and not surpris-
ingly, there is enhanced expression in inflammatory skin
diseases (allergic contact dermatitis, AD, and psoriasis)
(Homey et al, 2002). Therefore, it appears that CCL27/
CCR10 are important for Tcell homing to the skin regardless
of whether the memory T cell is Th1 or Th2 polarized.
The importance of various chemokine ligands/receptor
pairs in the host response to a wide variety of pathogens
has been demonstrated in deficient mouse strains and has
been recently reviewed (see Table II) (Le et al, 2002; Power,
2003). Similarly, several groups have demonstrated im-
proved host survival as a result of overexpression of
chemokines in murine infection models (Le et al, 2002). Al-
though most of the literature supports the notion that
chemokine/chemokine receptors are important in host def-
ense, there are a few examples where chemokine/chemo-
kine receptor-deficient mice have improved survival
following pathogen exposure, suggesting that an overly
brisk innate response may not always be advantageous
(Table II, sections in bold).
It has been suggested that an exaggerated innate re-
sponse may result in chronic inflammatory or autoim-
mune diseases (Kobayashi and Flavell, 2004). Several dis-
eases that may develop as the consequence of an overly
robust chemokine-mediated, inflammatory response include
acute respiratory distress syndrome, glomerulonephritis, is-
chemia–reperfusion injury of the heart, viral mediated card-
iomyopathies, and possibly even herpes simplex virus-
associated erythema multiforme (Kobayashi and Flavell,
2004). Conversely, there are disease states where the innate
response appears to be compromised, as has been ob-
served in atopic dermatitis, where the epithelial production
of antimicrobial peptides and the neutrophil chemoattract-
ant, CXCL8, is inappropriately low compared with subjects
with psoriasis (Ong et al, 2002; Nomura et al, 2003).
Microbicidal activity A critical feature of an effective in-
nate immune response is the release of substances that
have direct antimicrobial actions. A wide variety of host
substances (e.g., hydrogen peroxide, RNase 7, nitric oxide,
lactoferrin, lysozyme, dermcidin, psoriasin) have been
shown to have antimicrobial activity in mammals but the
antimicrobial peptides (defensins (a and b) and cathelici-
dins) are the best characterized (Schittek et al, 2001; Ganz,
2003; Glaser et al, 2005). These effector proteins are pro-
duced by many of the same stimuli (IL-1, TNFa, TLR ligands)
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and cells (epithelial cells and phagocytic leukocytes) that
are responsible for chemokine release. Their direct antimi-
crobial activity is mediated by the insertion of the peptide
into the pathogens’ cell wall, resulting in the formation of
multiple pores and ultimately cell permeabilization or lysis
(Ganz, 2003).
Defensins and chemokines have overlapping functions
as they both have chemotactic activity. For example, many
defensins are leukocyte chemoattractants at nanomolar
concentrations, whereas tissue levels can reach the milli-
molar range (Yang et al, 2004). The a-defensins are chemo-
tactic for monocytes, naı¨ve CD4þ Tcells, CD8þ Tcells, and
neutrophils and exert their effects by binding to a not yet
identified, seven-transmembrane GPCR. The b-defensins
recruit immature DC and memory CD4þ T cells by interac-
tion with CCR6, whereas the human cathelicidin, LL-37,
chemoattracts neutrophils by binding to the seven-trans-
membrane GPCR, fMetLeuPhe (FMLP) receptor-1 (Op-
penheim et al, 2003).
Both defensins and chemokines have antimicrobial ac-
tivity. For example, truncated forms of the CXC chemokine,
CXCL7, isolated from the a-granules of platelets, named
thrombocidins, have antimicrobial activity against Gram-
positive and -negative bacteria (Yang et al, 2004). The IFNg-
inducible ELRneg CXC chemokines (CXCL9-11) were found
to have defensin-like activity against Escherichia coli and
Listeria monocytogenes with minimal inhibitory concentra-
tions (MIC) equal to, or 2–3-fold higher, than that necessary
for the a defensin, human neutrophil peptide-1 (Cole et al,
2001). The antimicrobial activity was thought to be due to
the high isoelectric point (pI410.6) and the specific distri-
bution of positively charged residues. Based on a few
shared structural motifs, and an abundance of cationic res-
idues shared by b-defensins and CCL20, it has recently
been shown that CCL20 also has antibacterial activity
mainly against gram-negative bacteria at low mg per mL
concentrations (Hoover et al, 2002). Recently, the CCR3 and
CCR10 ligand, CCL28, expressed at high concentrations on
mucosal surfaces of exocrine glands such as the parotid,
salivary glands, and within milk and saliva, and was found to
have antimicrobial activity against Candida albicans, Gram-
negative, and -positive bacteria (Hieshima et al, 2003). Yang
et al (2003) recently screened 30 human chemokines and
demonstrated that about two-thirds of these have antibac-
terial activity.
Taken together, it appears that many chemokines dem-
onstrate defensin-like antimicrobial activity. It remains to be
established whether these chemokines achieve the in vivo
concentrations necessary to exert their antimicrobial ac-
tions. This is indeed a likely scenario, as chemokine meas-
urements from biological fluids significantly underestimate
the levels achieved within tissue compartments, since
chemokines are immobilized by glycosaminoglycans pre-
sent on cell surfaces.
Cell activation Shortly after chemokines were recognized
for their effects on cell motility, it was appreciated that they
also had effects on cell activation. Their effects are numer-
ous and best characterized on granulocytes. They include
generation of oxygen radicals, lipid mediators, cytokines,
chemokines, upregulation, and conformational changes of
adhesion molecules, etc (Thelen, 2001). Leukocyte degran-
ulation, which results in the release of myeloperoxidase,
elastase, and lactoferrin from PMN, cationic proteins from
eosinophils, histamine and chemokines from mast cells,
and the respiratory burst from the macrophages, is impor-
tant for a rapid and effective innate immune response. Ad-
ditionally, chemokines also regulate NK cell proliferation and
cytotoxicity. For example, CCL2-5, CCL7, CCL8, CXCL10,
and CX3CL1 promote cytotoxic granule release, and
the two known CCR7 ligands, CCL19 and CCL21, can co-
stimulate IL-2-induced proliferation of CD56dim NK cells
(Taub et al, 1995).
Chemokines are also thought to have effects on imma-
ture DC (those expressing inflammatory chemokine recep-
tors) that may directly or indirectly alter their trafficking
patterns and ultimately their functional state. This could
have consequences for T helper cell polarization or even
immune priming or tolerance, and has recently been re-
viewed (Kapsenberg et al, 2003).
Polarization of CD4þ T cells As noted above, chemo-
kines are well recognized for their activation of myeloid cells
and only more recently, has this been extended to their ef-
fects on T helper cell differentiation (Kapsenberg et al,
2003). Optimal clearance of the various pathogens encoun-
tered by the human body requires the selective activation of
particular cellular and/or humoral immune responses. The
balance of Th1 or Th2 cytokines determines the types of
effector responses. The traditional paradigm is that the APC
provides T cells not only with the antigen and costimulatory
signals but also with a polarizing signal. Data recently re-
viewed suggest that the CCR5 ligands function similarly to
IL-12, IL-23, and IL-27 in promoting the development of a
Th1 phenotype, whereas CCR2 ligands have homology to
IL-4 or IL-10 with regard to their capacity to polarize T
helper cells toward Th2 differentiation (Kapsenberg et al,
2003). Interestingly, individuals with a CCR5 allele variant
(CCR5D32), which leads to a non-functional receptor, have
been shown to have reduced risk for the development of
asthma, a prototypic Th2 disease (Hall, 1999).
Chemokine receptor expression has also become a
marker of cell maturation, phenotype, and homing capacity
for T lymphocyte and DC (Muller et al, 2002). As noted in the
section on Cell recruitment, the interaction of chemokines
with specific receptors on Th1 (CCR5, CXCR3) and Th2
(CCR4, CCR8, and CCR3) cells is thought to be critical to
direct trafficking of these cells to tissue-specific areas
where their biological actions would be most effective. In
atopic dermatitis, a Th2-initiated disease, the percentage
of CCR5þ cells among circulating CD4þCD45ROþ T cells
was found to be significantly reduced, and this correlated
positively with the skin severity score and IFN-g production
(Okazaki et al, 2002). Conversely, in psoriasis, a Th1
condition, almost all of the skin-infiltrating CD3þ cells ex-
pressed CCR5 (Uchida et al, 2002).
Effects on structural cells A coordinated and successful
innate response to pathogens or injurious stimuli results in
containment of the pathogen and tissue repair (Figure 1).
Angiogenesis, or the growth of new blood vessels from pre-
existing vessels or capillaries, is a physiologic response that
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arises in the context of an innate immune response, as it
provides the tissue sites with a greater supply of relevant
leukocytes and mediators necessary to neutralize the path-
ogen. Only recently have studies demonstrated that
chemokines also communicate with structural cells (e.g.,
epithelial cells, endothelial cells, fibroblasts, and smooth
muscle cells), and that this is the basis for their angiogenic,
angiostatic, and wound repair actions.
Structural cells are thought to play a vital role in the reg-
ulation of leukocyte trafficking into organs such as the skin
(Stellato and Beck, 2000). Our laboratory and others have
demonstrated that these structural cells express a number
of chemokine receptors, suggesting that chemokines may
have autoregulatory or juxtaregulatory functions (Petering
et al, 2001; Stellato et al, 2001; Loveless et al, 2003).
Chemokine receptors have been identified on structural
cells in normal as well as in inflammatory tissues: CCR3
immunoreactivity has been detected on airway epithelium
from asthmatics, and patients with idiopathic hype-
reosinophilia (Stellato et al, 2003), and on keratinocytes from
skin biopsies of AD subjects (Petering et al, 2001). In vitro
studies have demonstrated that these receptors are func-
tional, based on agonist-induced intracellular Ca2þ flux, or
phosphorylation of downstream signaling proteins (Stellato
et al, 2001; Eddleston et al, 2002; Viedt et al, 2002). The
expression of these receptors can be regulated in vitro by
inflammatory mediators such as TNFa, IL-1b, or LPS (Stellato
et al, 2001; Eddleston et al, 2002; Lundien et al, 2002), in-
dicating that the function they convey is likely to be altered
by an innate immune response. Recent research demon-
strates that the biological actions of chemokine receptors on
structural cells include cell proliferation, chemotaxis, and the
expression of proinflammatory and profibrotic genes.
The first function attributed to chemokine receptors ex-
pressed on structural cells was uncovered by Strieter et al
(1992), who demonstrated that a member of the CXC
chemokine subfamily CXCL8 was angiogenic. Subsequent-
ly, it was shown that ELRþpos CXC chemokines, such as
CXCL1, CXCL5, and CXCL8, promote angiogenesis, as well
as neutrophil migration (see Leukocyte recruitment). It is
interesting to note that angiogenesis is another biological
action shared by antimicrobial peptides (LL-37) and
chemokines (Elsbach, 2003). The interferon g-induced,
ELRneg chemokines, CXCL9, CXCL10, and CXCL11, which
are CXCR3 agonists, instead display angiostatic properties.
These chemokines were able to inhibit angiogenesis in nude
mice, suggesting that these chemokines mediate their
effects independent of their actions on T cell recruitment
(Gurtsevitch et al, 1988).
Another biological process in which chemokine recep-
tors appear to play an active role is wound repair. Disruption
of the epithelial barrier triggers a multi-step process, in
which the cells at the edge of the wound need to migrate,
proliferate, and differentiate in an effort to restore the in-
tegrity of the skin or mucosal surface. Along these lines,
CCR2 and CCR3 expressed on airway epithelial cells have
been reported to mediate CCL2- and CCL24-induced pro-
liferation and chemotaxis of the airway epithelial cells (Lun-
dien et al, 2002; Stellato et al, 2003). Both effects appear to
be specific, as blocking antibodies or small-molecule in-
hibitors abrogated them. Similarly, keratinocytes have been
shown to proliferate in response to CXCR2 and CCR3 lig-
ands (Metzner et al, 1999; Petering et al, 2001).
Gene expression induced by chemokine stimulation of
structural cells provides further proof that these receptors
are important in inflammation and wound repair. For exam-
ple, gene array studies of epithelial cells stimulated with a
CCR3 ligand have noted upregulation of numerous chemo-
kines, proinflammatory cytokines, and growth factors indi-
cating that chemokines can amplify proinflammatory
pathways while providing key signals important for tissue
repair/remodeling (Haley et al, 2000; Loveless et al, 2003;
Stellato et al, 2003).
In conclusion, chemokine receptors on structural cells
clearly mediate effects of the chemokine network that go
beyond the regulation of leukocyte trafficking, and expand
the role of these molecules to the involvement of processes
equally relevant for chronic inflammatory diseases and the
innate immune response, such as fibrosis, tissue remode-
ling, and angiogenesis.
Viruses: harnessing chemokines/chemokine receptors
to subvert host defenses As part of evolution, many in-
fectious agents have exploited the chemokine system to
improve their survival in the host and enhance their dis-
semination. Viruses, more than any other microbial class,
have taken lessons from host defense strategies to develop
protein homologs of chemokines (vCk), homologs of
chemokine receptors (vCkR) and unique viral products able
to bind chemokines (vCkBP) that ultimately lead to a sur-
vival advantage for the virus (Liston and McColl, 2003).
Viral-encoded chemokine agonist and antagonists are
expressed by large DNA viruses, specifically herpes and
poxviruses (Liston and McColl, 2003). For example, the
Kaposi’s sarcoma-associated herpesvirus (HHV8) encodes
a chemokine homolog, vMIP-II/K4, that acts as an agonist
to CCR3-, CCR8- and CXCR2-expressing cells (Crump
et al, 2001). This is likely done to promote HHV8 dissem-
ination. But this same chemokine homolog, vMIP-II/K4, acts
as an antagonist for cells expressing CCR1, CCR2, CCR5,
CXCR4, XCR1, and CCR10 (Crump et al, 2001). Similarly,
the HIV-1 transactivator protein (Tat) appears to mimic b-
chemokines, by recruiting monocyte/macrophages toward
HIV-producing cells, facilitating their infection (Albini et al,
1998). Cross-desensitization experiments suggest that Tat
may share receptors with CCL2, CCL7, and CCL5. Addi-
tionally, Tat may also modulate the host response, by de-
creasing the release of anti-HIV chemokines such as CCL3
and CCL4 from uninfected T cells (Zagury et al, 1998).
Expression by the vCkR can serve several purposes.
First, it allows the virally infected cell to migrate or prolif-
erate in response to chemokines to which they would
otherwise be unresponsive to. This can have obvious ad-
vantages, as it can help spread the virus to other regions of
the body and lead to greater viral load. Second, the vCkR
can act as a decoy receptor preventing the activity of the
endogenous chemokine, thus interfering with a robust in-
nate or adaptive immune response. Lastly, virally encoded
chemokine receptors may have constitutive signaling activ-
ity. This may result in general cell activation or more spe-
cifically, could promote angiogenesis and oncogenesis
(Liston and McColl, 2003).
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Viral binding proteins, CkBP, are not homologs of host
chemokine receptors. They are unique viral products with
no host homology (Liston and McColl, 2003). For example,
the poxvirus vCkBP-II binds CC chemokines with high af-
finity and thereby prevents interaction with their receptors,
preventing recruitment of leukocytes important for the in-
nate or adaptive immune response (Alcami et al, 1998). The
herpesvirus protein, vCkBP, has even broader actions,
binding to members of all chemokine subfamilies (C, CC,
CXC, and CX3C) (Liu et al, 2000). In summary, virus-
encoded chemokines are either antagonists that block
leukocyte recruitment to sites of infection, or agonists that
could enhance the recruitment of immune cells supporting
viral replication.
It is also recognized that chemokine receptors can facil-
itate viral entry into permissive cells (Le et al, 2003). Prob-
ably the most well-known examples are the demonstration
that HIV utilizes several chemokine receptors as co-recep-
tors (along with CD4) for viral entry and infection (Berger
et al, 1999) and the demonstration that Plasmodium vivax
and knowlesi invade RBC by binding to the chemokine re-
ceptor, DARC (Miller et al, 1975). The chemokine receptor
used varies based on the HIV isolate in general; CCR5 ap-
pears to be more important in primary HIV infection, where-
as CXCR4 acts as a co-receptor during disease progression
(Berger et al, 1999). This is supported by the finding that
individuals who are either homozygous or heterozygous for
the 32-bp deletion in the coding region of CCR5 are resist-
ant to HIV infection or progress more slowly to AIDS, re-
spectively (Berger et al, 1999). The fact that patients with
this detection were otherwise healthy increased the enthu-
siasm for the pharmaceutical development of a CCR5 an-
tagonist as an anti-HIV therapy, which is undergoing human
trials (Scozzafava et al, 2002).
Conclusion
The discovery of the chemokine family was a revelation for
investigators studying leukocyte recruitment. Finally, the
unique footprint of leukocytes recruited in each inflamma-
tory disease could be explained. It became increasingly
clear that chemokines probably orchestrate the trafficking
of almost all cells found in the body, but also that they
possess many other key biological effects. Few of these
effects are more important than those directed at containing
pathogens and responding to injury as outlined in this re-
view. Nevertheless, it has been suggested that an exagger-
ated innate response may result in chronic inflammatory or
autoimmune diseases. The pluripotency of chemokine ac-
tions suggests that they are central players in a variety of
inflammatory diseases, as well as in host defense, wound
repair, and tumorigenesis. To date, pharmacological efforts
have primarily focused on developing chemokine and
chemokine receptor antagonists as anti-inflammatory drugs
or as means to prevent HIV entry (Scozzafava et al, 2002).
The first human study to test the utility of a chemokine re-
ceptor antagonist in a chronic inflammatory disease tested
the effect of a CCR1 antagonist in adults with rheumatoid
arthritis (Haringman et al, 2003). In this 14-d study, they
observed a significant reduction in CCR1-bearing leu-
kocytes (CD4þ , CD8þ , and macrophages [CD68þ ]) in
the synovial tissues and a modest clinical improvement
(Haringman et al, 2003).
It remains to be seen whether the clinical consequences
of such drugs may also bring broader, unexpected effects,
such as an increased risk for infections. The idea that in-
flammatory chemokines are, to some extent, redundant
would predict that the use of a single chemokine or chemo-
kine receptor antagonist might have little effect on immunity.
On the other hand, we may find that a more prolonged use
of these agents will compromise the immune response to a
focused group of microbes, possibly only when they invade
a specific mucosal surface. Will chemokine receptor an-
tagonists affect a patient’s ability to mount a Th1 or Th2
response? Will some anti-chemokine strategies prevent
post-infection organ damage that too are the result of an
overly brisk innate or adaptive immune response? The an-
swers to at least some of these questions are forthcoming
as chemokine antagonists are developed for treatment of
inflammatory diseases, and as recombinant chemokines
are utilized as vaccine adjuvants and anticancer therapies.
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